PTEN

[Molecular Cancer therapeutics] Scientists investigated the response of PTEN wild-type prostate cancer cell lines to the dual PI3K/mTOR inhibitor DS-7423 alone or in combination with HER2 inhibitors or mGluR1 inhibitors.

[Hepatology] The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models.

[Current Stem Cell Research & Therapy] The authors explored the contribution of miRNAs in adipose-derived stem cell-extracellular vesicles to the treatment of cerebral ischemia.

[Stem Cell Research & Therapy] The authors investigated the effect of hematopoietic cells on MSCs using various methods, including flow cytometry, adipogenic and osteogenic differentiation analysis, quantitative PCR, western bloting, and microCT analysis.

[Nature Communications] Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.

[Hepatology] The authors performed a Sleeping Beauty transposon-based in vivo insertional mutagenesis screen in liver-specific Pten-deficient mice and identified tumor necrosis factor receptor-related factor 3 (Traf3) as the most significantly mutated gene in murine intrahepatic cholangiocarcinoma in a loss-of-function manner.